Dr Nathan on Updated Survival Outcomes With Tebentafusp in Metastatic Uveal Melanoma
November 8th 2023
Paul D. Nathan, MBBS, PhD, FRCP, discusses the 3-year survival data from the phase 3 IMCgp100-202 trial of tebentafusp-tebn in patients with previously untreated, HLA-A*02:01–positive metastatic uveal melanoma.